SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (861)8/3/2003 1:13:27 AM
From: Miljenko Zuanic  Respond to of 3557
 
If the speed of the IL-4/13-Trap is the same as for VEGF-T, maybe somewhere in 2XXX wemay get clue what is going on?

J. Clin. Invest. 112:332-344 (2003). doi:10.1172/JCI200316815.
Copyright ©2003 by the American Society for Clinical Investigation

Adenosine mediates IL-13–induced inflammation and remodeling in the lung and interacts in an IL-13–adenosine amplification pathway
Michael R. Blackburn1, Chun G. Lee2, Hays W.J. Young1, Zhou Zhu2, Janci L. Chunn1, Min Jong Kang2, Suman K. Banerjee1 and Jack A. Elias2
1Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, Texas, USA
2Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

Address correspondence to: Jack A. Elias, Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, S441-C, New Haven, Connecticut 06520-8057, USA. Phone: (203) 785-4163; Fax: (203) 785-3826; E-mail: jack.elias@yale.edu.

Received for publication September 3, 2002, and accepted in revised form May 6, 2003.

IL-13 is an important mediator of inflammation and remodeling. We hypothesized that adenosine accumulation, alterations in adenosine receptors, and adenosine–IL-13 autoinduction are critical events in IL-13–induced pathologies. To test this, we characterized the effects of IL-13 overexpression on the levels of adenosine, adenosine deaminase (ADA) activity, and adenosine receptors in the murine lung. We also determined whether adenosine induced IL-13 in lungs from ADA-null mice. IL-13 induced an inflammatory and remodeling response that caused respiratory failure and death. During this response, IL-13 caused a progressive increase in adenosine accumulation, inhibited ADA activity and mRNA accumulation, and augmented the expression of the A1, A2B, and A3 but not the A2A adenosine receptors. ADA enzyme therapy diminished the IL-13–induced increase in adenosine, inhibited IL-13–induced inflammation, chemokine elaboration, fibrosis, and alveolar destruction, and prolonged the survival of IL-13–transgenic animals. In addition, IL-13 was strongly induced by adenosine in ADA-null mice. These findings demonstrate that adenosine and adenosine signaling contribute to and influence the severity of IL-13–induced tissue responses. They also demonstrate that IL-13 and adenosine stimulate one another in an amplification pathway that may contribute to the nature, severity, progression, and/or chronicity of IL-13 and/or Th2-mediated disorders.



To: Miljenko Zuanic who wrote (861)8/14/2003 9:13:32 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 3557
 
<< 2. Revenue from Novartis collaboration? No draw from loan facility and related to 2003 clinical expense? And this should be FREE money, IF they hit target with PII? >>

They did!

From 10Q:

…Development expenses incurred during 2003 will be shared equally by the Company and Novartis. Regeneron may fund its share of 2003 development expenses through a loan (the “2003 Loan”) from Novartis, which will bear interest at a rate per annum equal to the LIBOR rate plus 2.5%, compounded quarterly. The 2003 Loan and accrued interest thereon will be forgiven should certain defined pre-clinical and clinical milestones be reached; otherwise, such amounts are payable on July 1, 2004. As of June 30, 2003, the 2003 Loan balance due Novartis, including accrued interest, totaled $5,147….

… Three months ended June 30, 2003 and 2002. Our total revenue increased to $10.5 million for the second quarter of 2003 from $5.6 million for the same period of 2002. Contract research and development revenue increased to $9.8 million for the second quarter of 2003 from $2.7 million for the same period of 2002, as we recognized $7.0 million of revenue related to our IL-1 Trap collaboration with Novartis. We recognize revenue in connection with the collaboration using the percentage of completion method in accordance with Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements (SAB 101). …

… Development expenses incurred during 2003 will be shared equally by Regeneron and Novartis. We may fund our share of 2003 expenses through a loan from Novartis that will be forgiven, together with accrued interest, should certain pre-clinical and clinical milestones be reached and is otherwise payable on July 1, 2004. As of June 30, 2003, we have drawn $5.1 million against this loan facility. In addition, at June 30, 2003, $4.3 million was receivable from Novartis for their share of IL-1 Trap development expenses incurred by Regeneron during the second quarter of 2003…